Aldeyra Therapeutics shares surge 24.87% after-hours driven by heavy $2 strike call option activity and bullish trader positioning.
ByAinvest
Monday, Mar 23, 2026 4:32 pm ET1min read
ALDX--
Aldeyra Therapeutics (ALDX) surged 24.87% in after-hours trading, driven by intense options activity in $2 strike price call contracts, which saw elevated leverage and turnover. The stock’s intraday rally of 20.7% earlier in the day, fueled by bullish positioning in short-term call options, continued into after-hours as traders capitalized on oversold technical conditions and high implied volatility. Despite a bearish sector backdrop for biotech stocks, ALDX’s move reflects speculative bets on a near-term rebound, with options data indicating strong demand for leveraged exposure. The FDA’s third rejection of Reproxalap, while a fundamental headwind, did not offset the immediate technical and options-driven momentum.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet